With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.169447-70-5,(S)-tert-Butyl 2-methylpiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.
Step 1: (S)-tert-butyl 4-(3,4-difluorophenyl)-2-methylpiperazine-1-carboxylate A mixture of 4-bromo-1,2-difluorobenzene (1 g, 5.18 mmol), (S)-tert-butyl 2-methylpiperazine-1-carboxylate (1.04 g, 5.18 mmol), t-BuONa (747 mg, 7.77 mmol), BINAP (40 mg, 0.06 mmol) and Pd2(dba)3 (20 mg, 0.02 mmol) in toluene (15 mL) was stirred at 80 C. for 3 hrs. The mixture was then purified by chromatography (silica, EtOAc/PE=1/8) to afford (S)-tert-butyl-4-(3,4-difluorophenyl)-2-methylpiperazine-1-carboxylate (921 mg, 2.95 mmol, 57%) as product. ESI-MS (EI+, m/z): 257.1 [M-55]+.
169447-70-5, As the paragraph descriping shows that 169447-70-5 is playing an increasingly important role.
Reference£º
Patent; Navitor Pharmaceuticals, Inc.; O’Neill, David John; Saiah, Eddine; Kang, Seong Woo Anthony; Brearley, Andrew; Bentley, Jonathan; (136 pag.)US2019/389843; (2019); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics